Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Multiple Sclerosis

Journal Scan / Research · November 13, 2024

Disease Activity in Pregnant and Postpartum Women With MS Receiving Ocrelizumab or Other Disease-Modifying Therapies

Neurology(R) Neuroimmunology & Neuroinflammation

 

Additional Info

Disclosure statements are available on the authors' profiles:

Neurology(R) Neuroimmunology & Neuroinflammation
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies
Neurol Neuroimmunol Neuroinflamm 2024 Nov 01;11(6)e200328, WZ Yeh, A Van Der Walt, OG Skibina, T Kalincik, R Alroughani, AG Kermode, MJ Fabis-Pedrini, WM Carroll, J Lechner-Scott, C Boz, S Ozakbas, K Buzzard, M Habek, NA John, A Prat, M Girard, P Duquette, SM Baghbanian, S Hodgkinson, V Van Pesch, G Laureys, B Willekens, J Prevost, M Foschi, K De Gans, D Horakova, EK Havrdova, R Karabudak, F Patti, PA Mccombe, D Maimone, A Altintas, R Ampapa, D Spitaleri, OHH Gerlach, MJ Sa, S Hughes, R Gouider, S Mrabet, RA Macdonell, R Turkoglu, E Cartechini, A Al-Asmi, A Soysal, J Oh, E Muros-Le Rouzic, S Guye, N Pasquarelli, H Butzkueven, VG Jokubaitis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading